BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Equities research analysts at William Blair issued their Q1 2020 earnings per share estimates for BioDelivery Sciences International in a report issued on Thursday, April 11th. William Blair analyst T. Lugo forecasts that the specialty pharmaceutical company will earn $0.00 per share for the quarter. William Blair also issued estimates for BioDelivery Sciences International’s Q2 2020 earnings at $0.01 EPS, Q3 2020 earnings at $0.03 EPS and Q4 2020 earnings at $0.05 EPS.

A number of other equities analysts have also recently weighed in on BDSI. Cantor Fitzgerald set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Thursday, December 27th. BidaskClub upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Friday, January 11th. Zacks Investment Research cut BioDelivery Sciences International from a “strong-buy” rating to a “hold” rating in a report on Friday, January 11th. Finally, Janney Montgomery Scott restated a “buy” rating and issued a $5.00 price target on shares of BioDelivery Sciences International in a report on Thursday, January 31st. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $5.79.

NASDAQ BDSI opened at $4.81 on Monday. The company has a market capitalization of $350.49 million, a price-to-earnings ratio of -6.59 and a beta of 0.46. BioDelivery Sciences International has a fifty-two week low of $1.70 and a fifty-two week high of $5.37. The company has a debt-to-equity ratio of 1.74, a current ratio of 3.07 and a quick ratio of 2.82.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.10). The firm had revenue of $18.03 million during the quarter, compared to the consensus estimate of $16.15 million. BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%.

Institutional investors have recently added to or reduced their stakes in the company. Advisor Group Inc. boosted its stake in shares of BioDelivery Sciences International by 56.3% during the 4th quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after buying an additional 3,943 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of BioDelivery Sciences International during the 4th quarter valued at approximately $147,000. Raymond James & Associates boosted its stake in shares of BioDelivery Sciences International by 14.9% during the 4th quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock valued at $171,000 after buying an additional 6,000 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of BioDelivery Sciences International during the 1st quarter valued at approximately $300,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of BioDelivery Sciences International during the 3rd quarter valued at approximately $255,000. Institutional investors own 56.89% of the company’s stock.

In other news, Director Francis E. Odonnell, Jr. sold 23,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $5.07, for a total transaction of $116,610.00. Following the completion of the transaction, the director now directly owns 544,187 shares in the company, valued at approximately $2,759,028.09. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Healthcare Master Fun Broadfin sold 2,000,000 shares of the stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $5.00, for a total value of $10,000,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 2,048,050 shares of company stock valued at $10,241,990. 13.26% of the stock is owned by company insiders.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Article: How do buyers and sellers choose a strike price?

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.